One isoform of the 14-3-3 family, 14-3-3s, plays a crucial role in the G2 checkpoint by sequestering Cdc2-cyclinB1 in the cytoplasm, and the expression of 14-3-3s is frequently lost in breast cancers. This loss of expression is thought to cause a G2 checkpoint defect, resulting in chromosomal aberrations. Since lung cancers frequently carry numerous chromosomal aberrations, we examined the DNA methylation status and expression level of the 14-3-3s gene in 37 lung cancer cell lines and 30 primary lung tumor specimens. We found that small cell lung cancer (SCLC) cell lines frequently showed DNA hypermethylation (9 of 13 lines, 69%), and subsequent silencing of the 14-3-3s gene. Among nonsmall cell lung cancers (NSCLC), large cell lung cancer cell lines showed frequent hypermethylation and silencing of 14-3-3s (4 or 7 lines, 57%). In contrast, in other NSCLC cell lines, hypermethylation occurred very rarely (1 of 17 lines, 6%). All eight primary SCLC specimens examined also showed a loss or signi®cant reduction in 14-3-3s expression in vivo, while a loss or reduction of 14-3-3s expression was very rare in primary NSCLC specimens (1 of 22 tissues, 5%). This is the ®rst description that indicates lung cancers frequently show signi®cant inactivation of the 14-3-3s gene mainly due to DNA hypermethylation in SCLC, but rarely in NSCLC, suggesting involvement of the 14-3-3s gene in lung tumorigenesis in a histological type-speci®c manner. Oncogene (2002) 21, 2418 ± 2424. DOI: 10.1038/sj/ onc/1205303 Keywords: lung cancer; 14-3-3s; methylation; MSP Lung cancer currently claims more than 160 000 lives annually as the number one cause of cancer deaths in the United States (Minna et al., 1997) , while it has also become the leading cause of cancer death in Japan, with over 50 000 fatalities annually. A better understanding of the molecular pathogenesis of this disease is urgently required to develop a preventative or therapeutic breakthrough to drastically reduce the number of deaths. Molecular biological studies have provided clear evidence of multi-step accumulations of multiple genetic and epigenetic alterations in both tumor suppressor genes and dominant oncogenes (Sekido et al., 1998) . Lung cancer cells have also been frequently shown to carry structural and numerical changes in chromosomes (Testa, 1996) . Proper cellcycle checkpoints are thought to maintain the genomic integrity, and their abrogation contributes to genomic instability (Dhar et al., 2000) . Recently, we found that chromosomal instability is a common feature of lung cancer cell lines in association with the presence of signi®cant aneuploidy (Haruki et al., 2001) , and that lung cancers frequently carry defects in the G1 and mitotic checkpoints, which may be correlated with chromosomal aberrations (Takahashi et al., 1989 (Takahashi et al., , 1999 .
The 14-3-3 proteins function as adaptor proteins recognizing phospho-serine motifs, and regulate the interactions and subcellular localization of signaling molecules. Recent evidence demonstrated that 14-3-3s protein plays a crucial role in the G2 checkpoint by sequestering Cdc2 ± cyclinB1 in the cytoplasm (Chan et al., 1999) , and that the expression of 14-3-3s is frequently lost in breast cancers (Ferguson et al., 2000) . We therefore speculated that 14-3-3s inactivation might also occur in lung cancers, which frequently carry numerous chromosomal aberrations. We report here, for the ®rst time, that in lung cancers, the 14-3-3s gene is frequently inactivated due to hypermethylation in a histological type-speci®c manner.
The DNA methylation status of the 14-3-3s gene in 13 SCLC and 24 NSCLC (adeno 9, squamous 6, Adenosquamous 2, large 7) cell lines was studied using the bisul®te conversion and methylation-speci®c PCR techniques (MSP) (Figure 1 ) (Ferguson et al., 2000) . The incidence of hypermethylation was dramatically dierent depending upon the histological type. Five (38%) of 13 SCLC cell lines showed methylationspeci®c PCR ampli®cation (Figure 1 , lane M) without unmethylated products (Figure 1 , lane U), suggesting complete hypermethylation. In addition, four SCLC cell lines (31%) showed PCR products both with methylation-speci®c and non-methylation-speci®c pri-mers, suggesting`partial' methylation. In total, nine SCLC cell lines (69%) demonstrated hypermethylation of the 14-3-3s gene. The other four SCLC cell lines showed unmethylated patterns. In addition to the SCLC lines, large cell lung cancer lines among NSCLC cell lines also frequently showed hypermethylation (three complete and one partial methylation in seven cell lines, 57%). In contrast, only one cell line of 17 other NSCLC cell lines showed partial DNA methylation (6%).
To con®rm quantitatively the correlation between 14-3-3s expression and DNA methylation status, the 14-3-3s expression was studied by Northern and Western blot analyses (Figure 2) . A loss or signi®cant reduction in 14-3-3s transcripts was observed in all six SCLC lines with hypermethylation, while two SCLC lines without DNA methylation showed abundant gene transcripts ( Figure 2a ). In addition, all four large cell carcinoma cell lines with hypermethylation showed a loss of 14-3-3s transcripts ( Figure 2b ). Only two of eight (25%) NSCLC lines (ACC-LC-176 and 73), excluding large cell carcinoma cell lines, showed only a moderate reduction in 14-3-3s transcripts, while the other six NSCLC cell lines (75%) showed abundant 14-3-3s transcripts ( Figure 2b) .
A signi®cant reduction in 14-3-3s expression was also detected at the protein level ( Figure 2c ). Similar to the ®ndings of Northern analysis, all six cell lines of SCLC with hypermethylation showed a loss or signi®cant reduction of 14-3-3s protein. In contrast, two SCLC cell lines without DNA methylation showed abundant 14-3-3s proteins. Large cell carcinoma cell lines with hypermethylation also showed a loss of 14-3-3s proteins.
Five cell lines of SCLC or large cell carcinoma showed a`partial methylation' pattern on MSP study, Figure 1 Methylation speci®c-PCR (MSP) of the 14-3-3s gene in lung cancer cell lines. Genomic DNA of lung cancer cell lines was treated with the sodium bisul®te conversion technique essentially as described (Clark et al., 1994) , and ampli®ed with PCR using primers speci®c for the methylated allele (sense; 5'-TGGTAGTTTTTATGAAAGGCGTC (+135/+157), anti-sense; 5'-CCTCTAACCGCCCACCACG (+220/+238)) or the unmethylated allele (sense; 5'-ATGGTAGTTTTTATGAAAGGTGTT (+134/+157), anti-sense; 5'-CCCTCTAACCACCCACCACA (+220/+239)) (Ferguson et al., 2000) . SCLC and large cell carcinoma cell lines frequently showed hypermethylation patterns, which were rarely observed in other NSCLC cell lines. PCR product with methylation-speci®c or unmethylated allele-speci®c primers are shown in lane M or U of each cell line. The ®ndings of MSP analysis of each cell line are also indicated below the gel (+, complete methylation; +, partial methylation; 7, unmethylated). (Ad, adenocarinoma; Sq, squamous carcinoma; AdSq, adenosquamous carcinoma; La, large cell carcinoma; Sm, small cell lung cancer) which might indicate clonal heterogeneity or the presence of both methylated and unmethylated alleles in the whole population. To clarify this issue, we performed sequencing analysis of cloned PCR products corresponding to the region with 7 CpG sites which we studied with MSP analysis. The methylation status of each CpG site in the cloned PCR products is shown in Figure 3 . The SCLC cell lines with the MSP pattern of`c omplete methylation' showed that almost all CpG sites were methylated (methylation rate; 96%), while in the SCLC cell lines showing the`unmethylated' MSP pattern almost all CpG sites were unmethylated (0*6%), supporting the results of MSP study. In the SCLC cell lines with the MSP pattern of`partial methylation', all alleles were methylated, although the methylation rate was slightly reduced (68*89%), and Figure 2 Expression analysis and summary of inactivation of the 14-3-3s gene in SCLC and NSCLC cell lines. Northern blot analysis was performed using 5 mg of total RNA according to the standard procedure (Osada et al., 1996) . The 397 bp RT ± PCR product was generated by RT ± PCR using primers (sense; 5'-CCTGCTGGACAGCCACCTCA, anti-sense; 5'-TGTCGGCCGTCCACAGTGTC), and was used as a probe for 14-3-3s mRNA after sequence veri®cation. Ten mg of cell lysate was applied to SDS ± PAGE and transferred to Immobilon P (Millipore). Western blot analysis was performed with anti-human 14-3-3s antibody (N-14) (Santa Cruz Biotechnology) and with anti-lamin B antibody (C-20) as an internal control (Santa Cruz Biotechnology). (a) 14-3-3s transcripts were frequently lost in SCLC lines, consistent with the DNA methylation status. (b) NSCLC lines showed abundant expression of the 14-3-3s gene, excluding large cell carcinoma cell lines with DNA methylation. (c) Alterations in 14-3-3s protein expression are also correlated with DNA methylation and transcriptional alterations. The 14-3-3s protein is hardly detected in SCLC and large cell carcinoma cell lines with DNA methylation. The results of MSP analysis are shown (+, +, 7) as in Figure 1 several unmethylated CpG sites were randomly dispersed. The ®rst and second CpG sites and sixth and seventh CpG sites corresponded to forward and reverse MSP primers, respectively. In some PCR clones, these pair of CpG sites were unmethylated. Those partially methylated DNA templates can be ampli®ed by unmethylated allele-speci®c primers as well as methylation-speci®c primers (data not shown). Therefore, the MSP pattern of`partial methylation' simply indicated a slight reduction of methylation rate in comparison with the MSP pattern of`complete methylation', and did not imply clonal heterogeneity or presence of both methylated and unmethylated alleles.
The expression levels of the 14-3-3s gene in 30 primary tumor specimens were immunohistochemically studied using anti-14-3-3s antibodies (Figure 4) . The marked histological type-speci®c alterations in 14-3-3s expression were also observed in primary specimens as well as in cell lines. Seven of eight SCLC cases (87.5%) showed a complete loss of staining for the 14-3-3s protein (Figure 4a ,b, closed arrow) in contrast to the strong staining of normal bronchial epithelium (Figure 4a ,b, open arrowheads). Only one case of SCLC showed 14-3-3s expression, but the intensity of the immunohistochemical staining was signi®cantly reduced (data not shown). Therefore, all eight SCLC tissue samples showed alterations in 14-3-3s expression (Figure 4d ). Of 22 NSCLC cases, only one (large cell cancer) (5%) showed reduced expression of the 14-3-3s protein (data not shown). The other 21 NSCLC showed abundant expression of the 14-3-3s protein along with normal bronchial epithelium (Figure 4c,d) .
Next, we also studied the DNA methylation status of primary SCLC tissue specimens using the MSP technique, and found that some (8/24, 33%), not all, SCLC tissue specimens without 14-3-3s expression showed a methylation pattern (data not shown). We further examined the precise in vivo status of DNA methylation in primary SCLC tissues using microdissected specimens to obtain pure tumor cells. In two microdissected SCLC specimens, one SCLC tissue (L421) clearly showed the complete methylation pattern, while the other SCLC tissue (L662) showed nearly complete unmethylated pattern (Figure 4e ), although in both tissues a loss of 14-3-3s expression was clearly detected with immunohistochemical analysis (Figure 4a,b) . We also found unexpectedly that normal lung tissues also showed a hypermethylation pattern (Figure 4f ). Immunohistochemical staining showed abundant expression of 14-3-3s proteins in the bronchial epithelium; while non-epithelial cells did not. Consistent with this observation, bronchial epithelia showed unmethylated patterns, while nonepithelial tissues (stroma) showed complete hypermethylation patterns (Figure 4f ). We remarked that the methylation of non-epithelial cells in normal mammary tissue was also recently reported (Umbricht et al., 2001) .
This study demonstrated for the ®rst time frequent and histological type-speci®c inactivation of the 14-3-3s gene in lung cancers. Although genetic alterations of 14-3-3s gene in lung cancers has not been reported to Figure 3 Sequencing analysis of DNA methylation of lung cancer cell lines. Genomic DNA treated with the sodium bisul®te conversion was ampli®ed with PCR using primers for 14-3-3s gene corresponding to just outside the region studied in MSP analysis (F2; 5'-GAAYGTTATGAGGATATGGTAG (+119/+140), R2; 5'-TAAACAACACCCTCCAAACAAC (+239/+260)). The PCR products were cloned into pBluescript II (Stratagene) and sequenced with ABI 3100 sequencer (Applied Biosystems). The methylation status of the seven CpG sites of each cloned PCR product was shown (open circle; unmethylated, closed circle; methylated). In ®ve cell lines of SCLC or large cell carcinoma showing a`partial methylation' pattern in the MSP study, most CpG sites were methylated, although the methylation rate was slightly less (68*89%) than that in the SCLC lines with`complete methylation' (96%). In contrast, the SCLC lines with an unmethylated MSP pattern and QG56 (squamous carcinoma) were almost completely unmethylated. The results of MSP analysis are indicated (M+, M+, M7) as in Figure 1 date (Nomoto et al., 2000) , recent reports showed that the expression of 14-3-3s is frequently lost in breast, gastric, and hepatocellular carcinomas (Ferguson et al., 2000; Suzuki et al., 2000; Iwata et al., 2000; Umbricht et al., 2001) . We found that expression of the 14-3-3s gene was frequently lost in SCLC and large cell Figure 4 Immunohistochemical analysis (IHC) and methylation of primary lung tumor specimens. A panel of 30 lung tumors consisting of eight small cell carcinomas, 13 adenocarcinomas, seven squamous carcinomas, and two large cell carcinomas, were examined in this study. Sections 3 mm thick from 10% formalin-®xed, paran-embedded specimens were prepared for IHC analysis. The standard avidin ± biotin ± peroxidase complex method was performed, using polyclonal anti-14-3-3s antibodies (a ± c). Microwave treatment in citrate buer (pH 6.8) was used for antigen retrieval. Non-neoplastic bronchial epithelial cells served as internal controls for antigen preservation. (a and b) Both primary SCLC specimens, L421 with methylation (a) and L662 without methylation (b), showed loss of 14-3-3s expression (arrow), while normal bronchial epithelia showed abundant expression (open arrowheads). A loss of 14-3-3s expression was similarly observed in almost all SCLC specimens. (c) IHC of a primary squamous carcinoma tissue specimen. Almost all NSCLC specimens showed abundant expression of 14-3-3s proteins (arrow) similar to normal bronchial epithelium (open arrowhead). (d) The ®ndings of IHC analysis of primary lung cancer specimens. All SCLC cases showed alterations in 14-3-3s expression in contrast to NSCLC cases. (e) Sequencing analysis of DNA methylation of primary SCLC specimens. DNA methylation status in two microdissected specimens of SCLC (L421 and L662) was studied as in Figure 3 . L421 showed hypermethylation, while in L662 the 14-3-3s gene was almost completely unmethylated, although both specimens showed the loss of 14-3-3s expression on IHC study (a and b). (f) MSP analysis of normal lung tissues. Normal bronchial epithelial cells showed unmethylated patterns, while non-epithelial cells (stroma) showed complete methylation patterns, resulting in a partial methylation pattern for the entire lung (normal lung). We also found that primary NSCLC tissues frequently showed a`partial methylation' pattern because of the contamination of non-epithelial tissues (data not shown). The immortalized normal bronchial cell line BEAS2B showed unmethylated patterns carcinomas, while other NSCLC did not show a loss of 14-3-3s expression. Therefore, these ®ndings suggest that inactivation of 14-3-3s may play a crucial role in SCLC and large cell carcinoma pathogenesis. The 14-3-3s gene is reported to be induced after DNA damage in a p53-dependent manner (Hermeking et al., 1997) , and to play a role in the G2 checkpoint by sequestering the Cdc2/cyclinB1 complex (Chan et al., 1999) . Experimental inactivation of the 14-3-3s gene causes a G2 checkpoint defect, and results in accumulation of chromosomal aberrations (Dhar et al., 2000) . Indeed, we recently found that SCLC cell lines frequently showed a defect of G2 checkpoint (Konishi et al., 2002) , which might be attributable to a loss of 14-3-3s expression. The G2 checkpoint defect may lead to chromosomal aberrations, and increase the sensitivity to the DNA damaging events. In this context, it is of interest that SCLC is highly sensitive to irradiation and chemotherapeutic agents. It will also be intriguing to investigate the integrity of G2 checkpoint in large cell carcinomas lacking 14-3-3s expression.
Histological type-speci®c methylation of the 14-3-3s gene suggests that the pathogenesis of SCLC and possibly a fraction of large cell carcinoma may be based on unique tumorigenetic steps, dierent from other NSCLC. The well-known growth inhibitory pathway of p16 INK4A ± cyclinD/Cdk4 ± Retinoblastoma (RB) was frequently disrupted in lung cancers in a histological type-speci®c manner. The p16
INK4A gene was frequently inactivated in NSCLC, mainly by hypermethylation of its promoter region, while RB, instead of p16 INK4A , was frequently disrupted in SCLC (Kelley et al., 1995) . A histological type-speci®c alteration was also noted in the KRAS gene. Activating mutations of the KRAS gene occur mainly in adenocarcinomas, occasionally in other NSCLC, but very rarely in SCLC (Tsuchiya et al., 1995) . Alternatively, the histological type-speci®c methylation of the 14-3-3s gene suggests that SCLC and a fraction of large cell carcinoma develop along unique dierentiation, dierent from other NSCLC. In this context, almost all SCLC and some large cell carcinomas show neuroendocrine features (Travis et al., 1991) , suggesting a possible correlation between 14-3-3s inactivation and neuroendocrine dierentiation.
In the study of cell lines, the clear correlation between hypermethylation and silencing of 14-3-3s was observed. However, in the analysis of microdissected specimens of primary SCLC tissues, one SCLC tissue showed an unmethylated pattern despite complete loss of 14-3-3s expression in the immunohistological analysis, suggesting that DNA methylation-independent mechanism may also be involved in the loss of 14-3-3s expression in primary tumors. In this regard, we have shown that an alteration of the chromatin structure plays a signi®cant role in the extinction of transforming growth factor-b type II receptor expression in lung cancers . It is possible that, in the established cell lines, the silencing of the 14-3-3s gene might have been enforced by hypermethylation, because all cell lines without 14-3-3s expression showed hypermethylation. Possible methylation-independent mechanisms in primary tumors remains to be elucidated to better understand the regulation of 14-3-3s expression.
In summary, we have shown for the ®rst time that 14-3-3s is frequently inactivated in SCLC and large cell carcinomas mainly by DNA hypermethylation. Histological type-speci®c inactivation of the 14-3-3s gene suggests that its biological role in carcinogenesis diers among SCLC, large cell carcinoma, and other NSCLC, and that diverse cell cycle checkpoint impairments may be involved in lung cancers, possibly in a histological type-speci®c manner. Clari®cation of the biological signi®cance of the 14-3-3s gene and its inactivation in SCLC may provide important clues for a better understanding of SCLC, and development of new therapeutic approaches for SCLC, the most aggressive type of lung cancer.
